🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

melcro53.wordpress.com

Selpercatinib Meets PFS End Point in Newly Diagnosed Advanced or Metastatic RET+ NSCLC onclive.com/view/selpercat… via OncLive.com #lcsm #lungcancer #RETmutation

Rare Mutations | Navigating Rare Mutations and Fusions rare-mutations.lungevity.org #lungcancer #lcsm

RET Inhibitors Drug Market Analysis, Share, Size and Forecast 2031 benzinga.com/pressreleases/… via Benzinga #lungcancer #biomarkers #lcsm

RET Inhibitors Drug Market Analysis, Share, Size and Forecast 2031 benzinga.com/pressreleases/… via Benzinga #lungcancer #biomarkers #LCSM

"If Your House Burns Down, Rescue the Dogs. At Least They'll Be Faithful to You." - Lee Marvin melcro53.wordpress.com/2023/09/29/if-…

Approach to Treating Patients with NSCLC and RET Fusions onclive.com/view/approach-… via @onclive #lcsm #lungcancer #RETmutation

U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors - businesswire.com/news/home/2023… #lcsm #lungcancer #biomarkers

FDA Approves Companion Diagnostic for Selpercatinib in RET Fusion+ Solid Tumors targetedonc.com/view/fda-appro… via @targetedonc #lungcancer #biomarkers

Advanced NSCLC patients with genomic profiling results prior to first-line (1L) therapy live 4x longer than those without

FoundationOne CDx Is Approved to Help Identify Patients Who Are Eligible for Selpercatinib oncnursingnews.com/view/foundatio… via @Oncology Nursing News

Retevmo Improves Progression-Free Survival in Patients with RET-Fusion Positive NSCLC curetoday.com/view/retevmo-i… via Cure

Selpercatinib Doubles Progression-Free Survival in RET-Mutated NSCLC - goo.gl/alerts/2pM9VF #GoogleAlerts #lungcancer #lcsm

LIBRETTO-431: Selpercatinib in RET Fusion–Positive NSCLC cancernetwork.com/view/libretto-… via @CancerNetwork®

Lessons from LIBRETTO-431 Trial in RET+ NSCLC ajmc.com/view/lessons-f… via ajmc @RETmutation Everyday Health Cristian Salazar 

A recent publication by Friedes et al. provides a contemporary update on the patterns of failure for patients with stage III NSCLC treated with the PACIFIC regimen at a tertiary academic medical center in Philadelphia. It suggests the local failure rate is less than 20%, which

💔 News re: Blueprint Medicines decision to de-prioritize development of Gavreto globally. This 💊 has proven safe, effective & VITAL for patients w/ RET+ cancers. We anxiously await 🗞️ of a hopeful partner so pt's can cont. to benefit from this amazing 💊 bit.ly/3HhB1mT

Sorry as a stage 4 nsclc pt, I am unimpressed. We seem to be setting the bar quite low with ORR and PFS in this study and in other ADCs: targetedonc.com/view/dato-dxd-…

This is a GREAT initiative! If you are a patient living with lung cancer, please contribute to this effort! 🙏🏽☑️💪🏽

Science has never brought me to tears until today. This poster was presented at #AACR25. The study used a cell line based on paired molecular profiling of biopsies derived from my dear friend Ivy Elkins cancer. Ivy's voice helped shape research, and now her cells are helping